Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets stomach cancer protein in 100-Patient trial

NCT ID NCT06962137

Recruiting now Disease control Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding the targeted drug zolbetuximab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or gastroesophageal cancer live longer. It includes 100 adults whose tumors have a specific protein called CLDN18.2. Participants receive the drug combination as a second treatment after first-line therapy has stopped working.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zolbetuximab (a targeted antibody) plus paclitaxel and ramucirumab (chemotherapy drugs)
What this could lead to
If it works, this could offer a more effective second-line treatment option for people with a specific type of stomach cancer.
What could go wrong
This is a Phase 2 trial with only 100 participants, so results are preliminary. The added drug may cause more side effects and might not improve survival compared to standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA GASTRIC CANCER ADENOCARCINOMA METASTATIC

Contacts and locations

Locations

  • AZ Delta Roeselare

    NOT_YET_RECRUITING

    Roeselare, Belgium

  • Cliniques Universitaires Saint-Luc Brussels

    NOT_YET_RECRUITING

    Brussels, Belgium

  • HUB

    NOT_YET_RECRUITING

    Brussels, Belgium

  • UZ Gent

    NOT_YET_RECRUITING

    Ghent, Belgium

  • UZ Leuven

    RECRUITING

    Leuven, 3000, Belgium

  • UZA

    NOT_YET_RECRUITING

    Antwerp, Belgium

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.